Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

Katja Weisel,Istvan Majer,Lucy DeCosta,Albert Oriol,Hartmut Goldschmidt,Heinz Ludwig,Marco Campioni,Zsolt Szabo,Meletios A. Dimopoulos

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

2019

Katja Weisel
Istvan Majer
Lucy DeCosta
Albert Oriol
Hartmut Goldschmidt
Heinz Ludwig
Marco Campioni
Zsolt Szabo
Meletios A. Dimopoulos

AbstractIn ENDEAVOR, carfilzomib and dexamethasone (Kd56) demonstrated significant improvement in progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd). Both agents were a...

Keywords:

Refractory Multiple Myeloma
Oncology
Multiple myeloma
Diabetes mellitus
Carfilzomib
Bortezomib
Medicine
Immunology
Dexamethasone
Internal medicine
in patient
indirect comparison

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations